New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
08:05 EDTIRWDIronwood details strategy to establish gastrointestinal therapeutics company
Ironwood Pharmaceuticals says it will detail its strategy to establish a gastrointestinal therapeutics company during its Investor Day. This strategy leverages Ironwood’s development and commercial capabilities in addressing GI disorders as well as its pharmacologic expertise in guanylate cyclase pathways, all of which is based on Ironwood’s pioneering work bringing forward LINZESS, the first FDA-approved product in a new class of GI medicines called GC-C agonists. To execute on its strategy, Ironwood will maximize LINZESS, leverage strong commercial capabilities, advance robust GI pipeline and guanylate cyclase (GC) research and orioritize investments in key value drivers. Ironwood is focusing its investments on its priority growth platforms. The company reduced the net cash used in operating activities from $93M in 1Q13 to $58M in the third quarter of 3Q13 and it expects this trend to continue through 2014 due to revenue growth and expense management. Ironwood reiterated that its projected 2014 LINZESS sales and marketing expenses with Forest are between $250M and $300M, as previously stated.
News For IRWD From The Last 14 Days
Check below for free stories on IRWD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IRWD

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use